The U.S. Food and Drug Administration’s (FDA) Blood Products Advisory Committee voted to recommend approval of Immucor Inc.’s HEA Molecular BeadChip Test as a safe and effective evaluation for blood group typing.
The test provides additional information about the composition of donor and patient blood, which may result in better matches for blood transfusion patients, especially for those who have received multiple transfusions.
It is the first molecular immunohematology test the FDA has accepted for review, Norcorss, Ga.-based Immucor noted.
To view the full article, please click here.